Social responsibility

Access to treatment

Expanding reliable access to high-quality treatments for people worldwide is at the core of our business strategy. This involves ensuring our products are available and affordable while supporting early and accurate diagnosis of diseases.

Improving diagnosis

Early and accurate diagnosis enables patients to access the medicines they need while easing the impact of diseases on both individuals and healthcare systems. We focus on a comprehensive approach to continuously improve diagnosis, combining targeted research and development, education and training for healthcare professionals, and efforts to raise disease awareness and understanding

Research and development

Across our therapeutic areas, we integrate key diagnostic considerations into clinical trial design. This includes the use of biomarkers and relevant laboratory parameters, refining criteria to reflect real-world diagnostic pathways, and including patient populations that are often underdiagnosed or difficult to identify in routine clinical settings. We collaborate with clinical experts and providers of diagnostic tools, and test systems to ensure our trial design follows current diagnostic standards and guidelines.

Education and training

We educate healthcare professionals about the prevalence, diagnosis, and management of rare diseases or conditions with high unmet needs. This helps to improve diagnosis rates and ensure that more patients can access appropriate care.

Key elements of our approach include:

• Scientific exchange: We participate in and organise international symposia and congresses and publish clinical research in peer-reviewed medical journals.

• Octapharma Academy: Our global platform, launched in 2009, enables healthcare professionals to exchange knowledge and experience through interactive workshops.

• Bleeding Management Masterclasses: The Masterclasses enable knowledge sharing through interactive real case discussions and collaborative learning.

• Digital platforms: Science Hub and One Source provide healthcare professionals with access to educational content, clinical data, and scientific exchange.

Awareness programmes

Raising awareness of Haematology, Imunotherapy and Citical Care conditions is crucial to ensure patients receive appropriate diagnosis and treatment.

Examples include:

• VWD awareness and diagnosis: The global online platform VWDtest.com provides educational content and tools, including a self-assessment questionnaire that patients can share with healthcare professionals to support diagnosis of von Willebrand disease (VWD), an often underdiagnosed and undertreated inherited bleeding disorder.

• Haemophilia A complication screening: With 8CHECK, we offer free complication screening for patients with haemophilia A and potential carriers. Insights into F8 gene mutation status may help assess the risk of developing inhibitors to therapeutic factor VIII (FVIII), a serious complication in haemophilia A management, and inform treatment decisions.

• Patient association support: We support patient associations such as the International Patient Organisation for Primary Immunodeficiencies (IPOPI) to raise awareness and strengthen understanding of relevant conditions. In 2025, we financially supported the launch of IPOPI’s Immunity Pulse podcast, giving patients, carers, physicians and experts a platform to share perspectives on the scientific and lived experience of primary immunodeficiencies (PIDs).

Product availability and affordability

In many countries access to essential medicines remains limited. We aim to make our products and therapies available and affordable to as many people as possible, while ensuring our capacity to innovate and grow the business.

Key elements of our approach include:

• Expanding our product portfolio: Our R&D efforts focus on diseases where there is a significant need for better treatment options. Our R&D pipeline includes more than 30 potential medicines across three therapeutic areas, with 12 new projects and 12 potential new indications for existing therapies.

• Extending product reach: We expand access by increasing registrations and reimbursement applications and conducting clinical trials in multiple countries.

• Offering support programmes: For Octapharma, supporting patients goes beyond providing therapies alone. We believe that improving outcomes also means helping patients navigate the practical and emotional challenges associated with living with a rare disease. In the US, for instance, we offer complimentary patient support programmes, such as IgCares, which supports people with primary immunodeficiency (PI), and Factor My Way, which supports people living with Haemophilia A or VWD.

• Optimising yields from every litre of plasma:

  We work to increase the number and yield of valuable proteins extracted from each litre of donated plasma as this directly influences our ability to manufacture more life-saving products for patients around the world depending on plasma-derived therapies for treatment.

• Engaging in self-sufficiency programmes: Through our contract manufacturing business, we support countries to ensure their populations have access to safe plasma‑derived medicines, using their own domestic blood or plasma donations.

Patients’ quality of life

Patients are at the core of our business, and we are committed to improving their quality of life. Our primary focus is to ensure the safety and efficacy of our products while continuously improving treatment outcomes for patients.

Product quality and patient safety

Product quality and patient safety are fundamental to our business. Our comprehensive quality management system and drug safety activities enable us to provide safe, effective, and reliable treatments to patients.

Improving outcomes for patients

Patients want medicines that are effective and convenient to use. Our focus is on improving the overall treatment experience, ensuring ease of use, and making our therapies as accessible and practical as possible.

Key elements of our approach include:

Patient-centric approach to R&D
We integrate patient perspectives into R&D through incorporating efficacy and quality-of-life endpoints into clinical trials and collaborating with researchers and patient advocacy groups to better understand patient needs and disease mechanisms. We also conduct post-approval studies to generate real-world evidence on the effectiveness and use of our treatments.

Convenience of drug application
Accessible, easy to use, and practical administration is a key aspect of the patient experience with our treatments. During our clinical trials, we test different applications, protocols and diagnostic algorithms to identify the best infusion settings for different patients.

An example of our commitment to providing convenient drug applications is our flexIG mobile phone app. The app includes instructional videos to support patients with at-home infusions, as well as a digital treatment diary that can easily be shared with doctors to improve monitoring.

Personalisation of treatment
Tailoring medical care to meet individual’s needs, preferences and lifestyle, is increasingly important to ensure that patients receive the most appropriate therapies. Personalisation can improve efficacy and tolerability, while reducing treatment burden.

Plasma donation

Donated plasma is the critically important resource for plasma-derived therapies used to treat millions of patients worldwide. 

In an environment where every drop of plasma counts, we strive to ensure the health and safety of donors, the productivity of our plasma donation centres and the quality of the donor experience.

Donor health and safety

Safeguarding the health, safety, and wellbeing of plasma donors is fundamental to our ability to provide life-saving plasma-derived medicines, and is upheld through robust quality systems, rigorous regulatory compliance, standardised procedures, and structured governance and oversight.

Donor experience

Maintaining a high-quality donor experience is important to ensuring a reliable supply of plasma for our medicines.

We engage and support donors through multiple channels, including our OctaApp, website, email, social media, alongside loyalty programmes that recognise continued donation and a self-service portal providing information on donation eligibility, referrals and estimated payment.

A multi-year initiative is enhancing the donation experience and operational efficiency at our donation centres, with renovations focused on reception areas, donor comfort and improved flow. Changes are informed by donor feedback and operational needs.

Donation centre quality and productivity

We continuously enhance the quality, efficiency and productivity of our plasma donation centres to support a reliable supply of plasma for our medicines. In 2025, we advanced initiatives focused on employee training and development, technology and equipment, streamlined and standardised procedures, and automation, while maintaining service quality and regulatory compliance.

Employee experience

Our success relies on attracting, developing and retaining talented people. We foster a collaborative and encouraging working environment with strong health and safety standards, offer training and development to support continuous learning and career growth, and cultivate an inclusive culture where everyone can thrive and reach their potential.

The expertise and commitment of our employees are essential for fulfilling our purpose and business strategy. In a rapidly evolving business environment, a qualified, skilled and adaptable workforce enables us to respond to changing needs, drive innovation and maintain operational excellence. By investing in learning and development, as well as employee engagement, we empower our people to perform at their best and serve patients effectively.

Working environment

We are committed to fostering a working environment where innovation flourishes, and employees feel valued, supported and empowered in order to deliver their best for patients every day. Our approach to fostering a collaborative and encouraging working environment includes not only a secure and stable job and good working conditions, but also strong team spirit, supportive colleagues, a human, friendly and respectful culture, an open and collaborative way of working, and accessible leaders.

Health and safety

Our industry is highly regulated, with stringent quality and safety standards. We aim for zero workplace accidents at all our locations as we are committed to ensuring that all employees return home safe and sound. Our approach combines providing supportive infrastructure and equipment, implementing preventive measures, engaging employees and encouraging active and healthy lifestyles, all with the aim of embedding health and safety in everyday work across our operations.

Training and development

Through our training and development programmes, we aim to motivate our employees, boost productivity and create a skilled, adaptable workforce that will help Octapharma to grow over the long-term. In addition to regulatory training requirements, employees receive role-specific training tailored to the position and nature of their work.

Inclusive culture

We are committed to an inclusive culture that embraces diversity, rejects discrimination, and fosters equity and belonging across our global operations. This commitment includes promoting an environment where all individuals are treated with dignity, respect and professionalism. Our approach to fostering an inclusive culture spans recruitment and hiring, retention measures, career development opportunities, performance evaluation, diversity awareness, as well as transparency and communication.

Local communities

We are committed to being a trusted partner in the communities where we operate. We focus on minimising our operational impacts while strengthening community relationships and positioning Octapharma as an employer of choice.

Our approach to engaging with local communities varies by site, reflecting local contexts and needs. Examples include:.